As part of its ongoing commitment to facilitating access to innovative testing, the Cerba laboratory now offers plasma pTau217 testing:

• Plasma pTau is a more accessible diagnostic orientation tool, requiring only a simple blood test.

This new assay supports the decision to perform additional tests, in particular lumbar puncture for  biomarkers measurement in CSF, in patients with cognitive impairment objectively confirmed by rigorous neurocognitive assessment.

Recent scientific data demonstrate :

• a strong correlation with amyloid status assessed by PET scan,
• superior performance compared to other currently available plasma biomarkers,
• excellent discrimination (AUC > 0.9).

Consult the catalog here

However, the test should not be performed on asymptomatic individuals to predict the risk of dementia.
This test is not validated for therapeutic monitoring, predicting the progression of Alzheimer’s disease, or assessing its severity.

-----------------------------------------------------------------------------------------------------------------

This advance is fully in line with the 2025-2030 French national strategy for the prevention and early detection of neurodegenerative diseases, especially in the era of new therapies.

Knowledge about Alzheimer’s disease has progressed considerably in recent years, particularly thanks to biomarkers.
For a long time, the diagnostic process relied solely on clinical assessment, but it now uses a multimodal approach combining:

• clinical evaluation and cognitive testing,
• brain imaging (MRI and PET scans),
• and biology (biomarkers).

Indeed, recent research shows that a specific biological signature can be detected up to 20 years before the appearance of the first clinical symptoms.

Consult the catalog here